Biota Scientific Management Pty Ltd

Australian Biomedical Company Pty Ltd.

Ausvir Therapeutics Pty Ltd

Betty Jin

Wen-Yang Wu

Keith G Watson

Darryl McConnell

Guy Y Krippner

Simon J F MacDonald

Stephen E Shanahan

Peter James Jenkins

Paul Arthur Jones

Wen Yang Wu

Van T T Nguyen

Phillip A Reece

Basil Danylec

Ee Ling Seah

Tho Van Phan

Laurence Mark Von Itzstein

Michael D Dowle

Simon P Tucker

Andrew McM Mason

Ee-Ling Seah

Henry Kenneth Windle

Laurence M Von Izstein

Tho V Phan

Joseph Noozhumurry Varghese

Peter Malcolm Colman

The present invention provides compounds for use in treating and/or preventing influenza. The compound comprises a first and second domain in which the first domain comprises at least one anchoring group which binds to the surface of influenza viruses and the second domain comprises at least one anionic group. The first and second domains are covalently linked. Also provided are pharmaceutically acceptable salts, solvates, prodrugs or stereoisomer of the compounds.

Compounds for medicinal applications

A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition.

Medicinal carbohydrates for treatment of respiratory conditions

Compositions including polymeric dialdehydes and compounds of 

Compositions for veterinary and medical applications

The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; Ris acetyl or trifluoroacetyl; X is CONH, NHCO or O; n is an integer from 2 to 6; and Y is C-Calkyl Ccycloalkyl, C-Calkoxyalkyl, an amino acid or dipeptide, or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a viral infection.

Dimeric compounds and their use as anti-viral agents

This invention relates to a compound capable of binding to a picornavirus capsid comprising two or more capsid binding moieties.

Antiviral agents

The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; Ris acetyl or trifluoroacetyl; X is CONH, NHCO or O; n is an integer from 2 to 6; and Y is C&#x2013;Calkyl Ccycloalkyl, C&#x2013;Calkoxyalkyl, an amino acid or dipeptide, or a pharmaceutically acceptable derivative thereof, methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a viral infection 

The invention relates to compounds of general formula (I); in which R is an amino or guanidino group; Ris acetyl or trifluoroacetyl; X is CONH, SONH, NHCO or NHCONH; m is either 0 or 1; n is an integer from 2 to 6; q is an integer from 0 to 3; and Y is hydrogen or an aromatic substituent, or a pharmaceutically acceptable derivative thereof; methods for their preparation, pharmaceutical formulations containing them or their use in the prevention or treatment of a viral infection 

Disclosed herein are compounds of formula II:wherein Alk, Z, X, X, R, &#x2014;Rand Rare defined herein, and their salts and pharmaceutically acceptable derivatives thereof, as well as other compounds of the general formula Het-A-Alk-W-Ar-C(X)&#x2550;NO-Xwhere Het, A, W and Ar are also defined herein. These compounds are useful in treating picornavirus infections in mammals. Novel intermediates of these compounds, as well as pharmaceutical compositions and methods of use, are also disclosed herein.

The invention provides novel macromolecules, methods for their preparation, pharmaceutical formulations thereof and their use as anti-influenza agents. The invention also provides a novel diagnostic method which can be used for detection of all types of influenza A and B virus. The macromolecular compound of the invention has attached to it one or more molecules (neuraminidase binders) which bind to the active site of influenza virus neuraminidase but which are not cleaved by the neuraminidase.

Macromolecular neuraminidase-binding compounds

This invention relates to novel dimeric compounds, methods for their preparation, pharmaceutical formulations thereof, and their use as antiviral agents. The compounds are particularly useful against influenza virus. In particular the invention provides a dimeric compound which comprises two neuraminidase binding groups attached to a spacer or linking group. Preferably the dimeric molecule comprises two neuraminidase-binding neuraminic acid (sialic acid) or cyclopentyl or cyclohexenyl carboxylic acid derivatives covalently attached to a common spacer group. Pharmaceutical compositions and methods of treatment, prophylaxis and diagnosis are disclosed and claimed.

Dimeric inhibitors of influenza neuraminidase

The invention provides a method of detection of influenza virus which utilizes compounds able to bind specifically to the active site of influenza virus neuraminidase, and novel compounds for use in the method.

Method of detection of influenza virus and compounds for use therein

Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid, pharmaceutical formulations thereof, methods for their preparation and their use in the treatment of viral infections, in particular influenza, are described.

Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic

N-Acetylneuraminic and derivatives of formula (I) ##STR1## pharmaceutical formulations thereof, their use in medicine, in particular as antiviral agents and methods for their preparation are described.

Growing community of inventors

Mount Waverley, Australia

Betty Jin